The cost of Invega Sustenna (paliperidone palmitate extended-release injectable suspension) without insurance can vary significantly depending on factors such as the dosage, the pharmacy, and geographic location. Patient assistance programs may be available to help reduce out-of-pocket expenses for those who qualify.
How Much Does Invega Sustenna Cost Without Insurance?
Without insurance, a single dose of Invega Sustenna can range from approximately $300 to over $600 [1]. This cost is for the medication itself and does not include any administration fees if given by a healthcare provider. Since Invega Sustenna is an extended-release injection typically administered monthly, the annual cost can be substantial for individuals paying entirely out-of-pocket.
Are There Ways to Lower the Cost of Invega Sustenna?
For eligible individuals without insurance or with high deductibles, pharmaceutical manufacturers often offer patient assistance programs. For Invega Sustenna, these programs might provide the medication at a reduced cost or even free of charge [2]. It is advisable to check the manufacturer's website or contact their patient support services for details on enrollment and eligibility criteria. Some pharmacies may also offer discount cards or have lower cash prices than others.
What is Invega Sustenna Used For?
Invega Sustenna is a long-acting injectable antipsychotic medication used to treat schizophrenia in adults [3]. It is also used to treat schizoaffective disorder in adults [3]. The extended-release formulation means it is administered less frequently than daily oral medications, typically once a month, which can improve adherence for some patients.
When Does the Patent for Invega Sustenna Expire?
The patent for Invega Sustenna has faced various legal challenges. While specific patent expiry dates can be complex due to multiple patents covering different aspects of the drug and formulation, many key patents related to Invega Sustenna have expired or are nearing expiration [4]. Information regarding specific patent statuses and their expiry timelines can be found on resources like DrugPatentWatch.com [4].
Can Generic Versions of Invega Sustenna Be Available?
Following patent expiry, the pathway opens for generic manufacturers to produce and market their own versions of the drug, known as generics or biosimilars for biologics. The availability of generic paliperidone palmitate injectable suspensions would likely lead to lower prices. However, the development and approval of generic injectable medications can be more complex than for oral drugs, potentially affecting the timeline for their market entry and the speed at which prices decrease.
Sources:
1. GoodRx. "Paliperidone Palmitate Cost."
2. Janssen Pharmaceutical Companies of Johnson & Johnson. "Patient Assistance Programs."
3. National Alliance on Mental Illness (NAMI). "Invega Sustenna."
4. DrugPatentWatch.com.